



For Release: February 15, 2010

## **ALBEMARLE® ANNOUNCES CUSTOM MANUFACTURING ALLIANCE WITH PHARMACORE®**

(Baton Rouge, LA) February 15, 2010 –[Albemarle Corporation](#) (NYSE: ALB), a leading global provider of custom manufacturing services, announced today it will partner with PharmaCore to provide manufacturing capabilities for customers with projects that require high volume capacity

This alliance allows a seamless technology transfer from PharmaCore to Albemarle, allowing PharmaCore customers to have long term, higher volume capacity for their pharmaceutical projects. Albemarle's custom manufacturing facilities include a network of manufacturing assets in [South Haven](#), Mich.; [Tyrone](#), Pa. and [Orangeburg](#), S.C. The South Haven plant offers capacities up to 4000 gallon reactors, while Orangeburg cGMP has reactor sizes of up to 16,000 gallons for much higher production volumes, typically greater than 200 mt/yr.

“We are happy that PharmaCore chose Albemarle's custom manufacturing business unit, [Fine Chemistry Services \(FCS\)](#), to expand on PharmaCore's expertise as a custom synthesis provider for their customers, said Steve Levan, Albemarle's vice president of fine chemistry services. I am confident that those customers will be pleased to have a premier production partner for their products.

“Our customers already benefit from PharmaCore's med-chem through GMP Pilot Plant capabilities. This new partnership with Albemarle will complete the process,” said Brian Swierenga, PharmaCore's vice president of GMP Operations. “We have formed long business relationships with many of our customers, synthesizing first batches for toxicology continuing through lab process development and ultimately providing GMP material for Clinical Trials. This new Albemarle partnership offers an opportunity to transfer that learned technology to full-scale manufacturing.”

Albemarle's Fine Chemistry Services (FCS) division is a leading provider of products and services, as well as custom manufacturing or process scale-up assistance for to the chemical industry. The FCS division boasts rapid response time and flexible manufacturing plants, including three cGMP plants in the United States and several custom manufacturing plants in the United States and Europe.

### **About Albemarle**

Albemarle Corporation, headquartered in Baton Rouge, Louisiana, is a leading global developer, manufacturer, and marketer of highly-engineered specialty chemicals for consumer electronics; petroleum and petrochemical processing, transportation and industrial products, pharmaceuticals, agricultural products, and construction and packaging materials. The Company is committed to global sustainability and is advancing its eco-practices and solutions in its three business segments, [Polymer Solutions](#), [Catalysts](#), and [Fine Chemicals](#). Albemarle



employs over 4,100 people and serves customers in approximately 100 countries. To learn more, visit [www.albemarle.com](http://www.albemarle.com).

### **About PharmaCore**

PharmaCore®, Inc., headquartered in High Point, NC, is an industry leader in custom organic synthesis, using diverse chemistries to produce pharmaceutical intermediates and API's. The company's business offerings consist of a variety of chemistry outsourcing services, including: medicinal chemistry services; chemical process and development; cGMP scale-up; and GMP analytical services. PharmaCore has served customers globally since 2000. Additional information is available at [www.pharmacore.com](http://www.pharmacore.com).

**Media Contact: Brandi Narez**, (225) 388-7505, [Brandi.Narez@albemarle.com](mailto:Brandi.Narez@albemarle.com)

**Investor Relations Contact: Sandra Rodriguez**, (225) 388-7654, [Sandra\\_Rodriguez@albemarle.com](mailto:Sandra_Rodriguez@albemarle.com)

*"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Albemarle Corporation's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K.*